Related Experiment Video

Updated: Aug 8, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: July 1, 2013

Structure-based approaches to inhibition of erbB receptors with peptide mimetics

Alan Berezov1, Mark I Greene, Ramachandran Murali

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, and the Abramson Family Cancer Research Institute, Philadelphia, PA 19104, USA.

Immunologic Research
|July 15, 2003
PubMed

Insights

Researchers developed small-molecule peptide mimetics that mimic antibodies targeting epidermal growth factor (EGF) receptors (erbB). These mimetics offer a novel, non-cytotoxic approach to cancer treatment by blocking erbB signaling pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Epidermal growth factor (EGF) receptor tyrosine kinases (erbB) are overexpressed in many human cancers.
  • High erbB expression correlates with advanced disease and poor prognosis.
  • Targeting erbB signaling represents a promising non-cytotoxic cancer therapy strategy.

Purpose of the Study:

  • To design small-molecule peptide mimetics that replicate the function of anti-erbB monoclonal antibodies (MAbs).
  • To explore structure-based strategies for erbB receptor blockade using peptide mimetics.
  • To investigate targeting receptor dimerization interfaces for therapeutic intervention.

Main Methods:

  • Development of peptide mimetics based on the structure and function of anti-erbB rhu MAb 4D5.
  • Utilizing structure-based drug design to target erbB receptor dimerization.
  • Evaluating peptide mimetics for their ability to block erbB signaling.

Main Results:

  • Successfully designed peptide mimetics that mimic anti-erbB MAb 4D5 properties.
  • Identified a structure-based strategy targeting receptor dimerization interfaces.
  • Demonstrated potential for peptide mimetics in blocking erbB signaling.

Conclusions:

  • Small-molecule peptide mimetics offer a novel therapeutic strategy against erbB-driven cancers.
  • Targeting receptor dimerization interfaces is a viable approach for erbB blockade.
  • Peptide mimetics provide a promising non-cytotoxic alternative for cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...